Loading
companiesCompany
Hetero Drugs
A privately held Hyderabad generics group, the world's largest maker of HIV antiretrovirals, which launched Indian biosimilars of rituximab in 2015 and bevacizumab in 2016.
Overview
Hetero Drugs was founded in 1993 by B. Parthasaradhi Reddy, formerly chief technologist at Dr. Reddy's, and operates in more than 145 countries with over 30,000 employees. Best known as the largest producer of antiretroviral drugs and for low-cost hepatitis C generics, it has built a biosimilars portfolio for India that includes rituximab (2015, for non-Hodgkin lymphoma and chronic lymphocytic leukaemia), darbepoetin alfa (2015) and bevacizumab (2016, for metastatic colorectal cancer), and it supplies oncology active ingredients and generics globally.
Headquarters
Hyderabad, IN
Scorecard
All companies#81of 1244 companies, score 56
- approved products +12
- targets +4
- modalities +2
- regions +8
- registry trials +30
2 approved, 0 in phase 3, 0 earlier, 2 targets, 4,438 registry studies. Formula on the scorecards page.
Type
Website
Founded
1993
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
Similar pages
- IdeaMake the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab
Shares Biosimilar, Prices and value, Rituximab, Bevacizumab.
- CompanyBiocon Biologics
Shares Biosimilar, VEGF / VEGFR, Prices and value, Bevacizumab.
- CompanyDr. Reddy's Laboratories
Shares Biosimilar, CD20, Prices and value, Rituximab.
- CompanyBiocon
Shares Biosimilar, Prices and value, Bevacizumab, Most of the world has almost no cancer care.
- CompanyMabion
Shares Biosimilar, Rituximab.
- TermBiologics Price Competition and Innovation Act 2010
Shares Biosimilar, Prices and value, Rituximab, Bevacizumab.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Prices and value, Most of the world has almost no cancer care, Monoclonal antibodies.
- IdeaDrop the extra switching studies for interchangeable oncology biosimilars
Shares Biosimilar, Prices and value.
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)